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a b s t r a c t
Excessive adventitial neovascularization is one of thehallmarks of atherosclerotic plaqueprogression and
is associated with an increased plaque burden by facilitating leukocyte inﬂux and perivascular inﬂamma-
tion. Statins act atheroprotective by reducing plasma cholesterol levels and by quenching inﬂammation,
but recent studies suggest that they may also affect neovascularization.
In this study, we aimed to investigate this notion in apoE−/− mice. Advanced carotid artery lesions
were induced by perivascular collar placement in mice on western type diet or diet supplemented with
atorvastatin (0.003%, w/w). Atorvastatin treatment did not affect diet induced body weight gain and did
not lower plasma total cholesterol levels. Plaque size at 8 weeks after collar placement was signiﬁcantly
reduced in atorvastatin treated mice compared to control mice, while also necrotic core size was signif-holesterol
ndothelial cell
icantly lower in atorvastatin treated mice. Interestingly, atorvastatin treatment reduced the number of
perivascular CD31+ neovessels by almost 40%. Furthermore, endothelial proliferation was signiﬁcantly
inhibited by atorvastatin treatment in vitro.
In conclusion, atorvastatin treatment inhibits plaque development in ApoE deﬁcient mice independent
of plasma total cholesterol levels. Given the profound inhibition of adventitial neovascularization, we
propose that statins may partly exert their protective effects by modulating this process, identifying yet
mechanother atheroprotective
. Introduction
Acute cardiovascular syndromes (ACS) such as myocardial
nfarction and stroke are commonly caused by erosion or rupture
f an unstable atherosclerotic plaque. Both lipid accumulation and
nﬂammation have been regarded to contribute substantially to
he initiation and progression of atherosclerosis, the underlying
ause of ACS [1,2]. Inhibitors of 3-hydroxy-3-methylglutaryl coen-
ymeAHMG-CoA reductase (statins) have evolved into thedrugs of
hoice to lower elevated lipids levels [3].While the therapeutic efﬁ-
acy of statins in cardiovascular disorders has been established in
umerous studies, evidence ismounting that statinsprotect against
ardiovascular disorders not only by virtue of their hypolipidemic
ctivity but also by quenching NFB [4] and by increasing PPAR
5,6] as well as PPAR activation [7]. Both processes are deemed
o affect not only vascular inﬂammation but also angiogenesis, a
rocess widely regarded as a risk factor in atherosclerosis [8]. In
ffect, Panigrahy et al. have demonstrated that PPAR activation
∗ Corresponding author. Tel.: +31 (0) 71 5276213; fax: +310 (0) 71 5276032.
E-mail address: i.bot@lacdr.leidenuniv.nl (I. Bot).
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inhibits angiogenesis by reducing VEGF synthesis at a transcrip-
tional level [9] and enhances endothelial cell apoptosis [10]. In
addition, Oitzinger et al. have shown that the ability of endothe-
lial cells to form capillary tubes in a matrigel assay was impaired
after inhibition of NFB activation [11], while endothelial cell sur-
vival was governed in part by NFB [12]. Current literature on
statin treatment andneovascularization is rather contradictory. For
example, Kureishi et al. demonstrated that simvastatin promotes
angiogenesis in normocholesterolemic animals [13], while more
recently it was shown that atorvastatin strongly induced angio-
genesis by enhancing the expression of angiogenic cytokines such
as VEGF, Ang-1, Ang-2 and eNOS, and by increasing HO-1 and EPC
numbers in a hindlimb ischemia model [14]. In contrast, atorvas-
tatin was demonstrated to impair myocardial angiogenic response
to chronic ischemia [15]. In human endothelial cells, statin treat-
mentwas shownto induce thrombomodulinexpressionwhichmay
be favorable in disorders associated with endothelial dysfunction
Open access under the Elsevier OA license.[16]. Wilson et al. showed that simvastatin treatment inhibited the
expansion of the vasa vasorum in pigs [17]. Likewise, cerivastatin
appeared to have anti-angiogenic effects in a panel of in vitro and
in vivo models [18,19]. These discrepancies may arise from differ-
ences in experimental setup, such as animal model, diet and statin
2 lerosis 214 (2011) 295–300
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osage [20]. Indeed, atorvastatin affected endothelial function in a
ose-dependent manner, being pro-angiogenic at 10nM, and anti-
ngiogenic in the M range [21].
Microvessel formation in the intima and adventitia of advanced
therosclerotic plaques is increasingly considered as an important
actor in plaque destabilization [8,22]. The PPAR andNFBmodula-
ory activity of statins led us to propose that statins may lower the
isk of acute cardiovascular syndromes at least partly by inhibit-
ng plaque neoangiogenesis. In this study we aimed to establish
he effect of atorvastatin treatment of apoE−/− mice on perivas-
ular microvessel formation in advanced atherosclerotic plaques.
e demonstrate that atorvastatin treatment inhibits atheroscle-
otic plaque development independent of cholesterol levels and
n addition reduces the number of perivascular CD31+ microves-
els. Our study thus identiﬁes an alternative mechanism by which
torvastatin treatment may prevent atherogenesis.
. Materials and methods
.1. Animals
All animal works were performed in compliance with the Dutch
overnment guidelines.Male apoE−/− mice, obtained from the local
nimal breeding facility, were fed a Western type diet, containing
.25% cholesterol and 15% cacao butter (SDS, Sussex, UK). After 2
eeks of diet feeding, carotid artery plaque formation was induced
y perivascular collar placement inmale apoE−/− mice as described
reviously [23], after which the mice were fed either Western-type
iet (control) or Western-type diet supplemented with a low dose
f atorvastatin (0.003%, w/w) [24]. After 8 weeks of atorvastatin
reatment, the mice were anaesthetized and in situ perfusion and
arotid artery embedding occurred as described previously [23].
ransverse 5m cryosections were prepared on a Leica CM 3050S
ryostat (Leica Instruments) in a proximal direction for histology
nd immunohistochemical analysis.
.2. Histology and morphometry
Cryosections were stained with hematoxylin (Sigma–Aldrich,
wijndrecht, The Netherlands) and eosin (Merck Diagnostica).
acrophage content of the lesions was assessed using a rat
onoclonal MOMA-2 antibody (Serotec, Kidlington, Oxford, UK).
ollagen was visualized using a Masson’s Trichrome staining kit
Sigma–Aldrich). Mast cells and neutrophils were visualized by
taining of cryosections with naphthol AS-D chloroacetate esterase
Sigma–Aldrich). Endothelial cells were visualized by incubation
ith a CD31 (PECAM-1) antibody (1:50, Thermo Fisher Scientiﬁc)
vernight at 4◦, after which the slides were incubated with Pow-
rvision Ready to use Poly-HRP anti Rabbit IgG (Immunologic,
uiven, The Netherlands) for 1h at room temperature and sub-
equently stained with Nova Red. Nuclei were visualized with
ematoxylin.
Morphometric analysis (Leica Qwin image analysis software)
as performed on hematoxylin-eosin stained sections of the
arotid arteries at the site of maximal stenosis (controls: n=12,
torvastatin: n=11). The number of perivascular CD31+ microves-
els, mast cells and neutrophils were assessed manually. MOMA-2
nd collagen positive areas were quantiﬁed by Leica Qwin image
nalysis software. All morphometric analyses were performed by
linded independent operators (I.M.L./I.B.)..3. Cell culture
The mouse endothelial cell line H5V was cultured in a
umidiﬁed atmosphere (5% CO2) at 37 ◦C in Dulbecco’s Modi-
ed Eagle Medium (DMEM) containing 10% Foetal Bovine SerumFig. 1. Oral atorvastatin treatment (0.003%, w/w) does not affect plasma total
cholesterol levels in apoE−/− mice throughout the experiment. Open symbols indi-
cate cholesterol levels in atorvastatin treated mice, closed symbols that of control
diet fed mice.
(FBS), 2mmol/L l-glutamine, 100U/mL penicillin and 100g/mL
streptomycin (all from PAA, Cölbe, Germany). To measure cell
proliferation, H5V cells were detached by short incubation with
trypsin-EDTA (PAA) and seeded at a density of 4.0×104 cells per
well. The cells were allowed to attach, serum starved in DMEM
containing 1% FBS for 8h to synchronize cell cycle and incu-
bated overnight with medium containing atorvastatin or control
medium. After incubation 0.5Ci [3H]thymidine (GE healthcare)
per well was added and the cells were incubated at 37 ◦C for 5h.
[3H]Thymidine incorporation was quantiﬁed in a liquid scintilla-
tion analyzer (Packard 1500 Tricarb, USA), n=4 per concentration
used.
To measure the effects of atorvastatin on endothelial tubule for-
mation, H5V cells (4×104 cells/well) were plated on Matrigel (BD
Biosciences) coated plates in the presence or absence of atorvas-
tatin. After 16h, representative pictures were taken from each well
and the number of sprouts (measured by the number of cellular
extensions) relative to cellular surface area was determined using
Leica Qwin image analysis. The experiment was performed in trip-
licate and of each sample three microscopic ﬁelds were analyzed.
2.4. Statistical analysis
Data are expressed as mean± SEM. A 2-tailed Student’s t-test
was used to compare individual groups. Non-parametric data were
analyzed using a Mann–Whitney U test. A level of P≤0.05 was
considered signiﬁcant.
3. Results
We delineated the effect of atorvastatin treatment on
atherosclerotic lesion progression. Atherosclerotic plaques were
induced in apoE−/− mice by non-constrictive perivascular col-
lar placement at the carotid arteries. During 8 weeks of lesion
development, the mice were fed plain Western-type diet (control)
or Western-type diet supplemented with 0.003% (w/w) atorvas-
tatin. During the study, atorvastatin treatment did not affect body
weight gain (data not shown) and did not lower average plasma
total cholesterol levels (control: 1357±45 versus atorvastatin:
1354±46mg/dL, P =NS, Fig. 1). Despite the unaltered plasma
lipid proﬁle, carotid artery plaque size at 8 weeks after collar
I. Bot et al. / Atherosclerosis 214 (2011) 295–300 297
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agniﬁcation).
lacement was reduced by almost 40% from 85±11×103m2 in
ontrol mice to 52±9×103m2 in the atorvastatin treated mice
P<0.05, Fig. 2A). Media size did not differ between the groups
47±3×103m2 in control mice to 41±2×103m2 in the ator-
astatin treated mice, Fig. 2B), while also intima/media ratio and
ntima/lumen ratio were not signiﬁcantly affected by atorvastatin
reatment. Furthermore, the relative necrotic area was reduced by
5% from 42±4% in control mice to 28±5% in atorvastatin treated
ice (P<0.05, Fig. 2C).
As to plaque morphology, atorvastatin treatment signiﬁcantly
educed thenumberof perivascular CD31+ neovessels in the adven-
itia by over 40% (6.6±1.1 versus 11.1±1.6 CD31+ neovessels/mm2
erivascular tissue for controls; P<0.05, Fig. 3) pointing to an
nhibitory effect of atorvastatin on inﬂammatory angiogenesis.
OMA-2 macrophage positive area and collagen content, as mea-
ured with a Masson’s Trichrome staining did not differ between
he groups (Fig. 4A and B). As we and others have previously shown
hat activation of adventitial mast cells leads to an acute deteriora-
ion of plaque stability with intraplaque hemorrhages and de novo
ell inﬂux [25], and mast cells were seen to harbor potent pro-
ngiogenic activity, we studied whether mast cell numbers and
ctivation status were affected by atorvastatin treatment. How-
ver, atorvastatin did not alter the number of perivascular mast
ells (controls: 3.3±0.6mast cells/mm2 perivascular tissue versus
torvastatin: 2.7±0.8mast cells/mm2 perivascular tissue, Fig. 4C),
hile the percentage of activated mast cells tended to be reducedrom 57±11% in controls to 38±12% activated mast cells in the
torvastatin treated mice. Also the number of perivascular neu-
rophils remained unaffected by atorvastatin treatment (controls:
7±16neutrophils/mm2 perivascular tissue versus atorvastatin:
2±17neutrophils/mm2 perivascular tissue, Fig. 4D). These datae diet for 8 weeks) resulted in a signiﬁcant reduction in atherosclerotic plaque
d unaffected (B). (C) Relative necrotic core size was also signiﬁcantly reduced by
rtery lesions from a control (left) and an atorvastatin treated ApoE−/− (right, 100×
suggest that atorvastatin at the dose used affects plaque size in
particular by affecting perivascular neovascularization.
To assess whether atorvastatin affected endothelial prolif-
eration, we stimulated mouse endothelial cells (H5V cells)
with increasing concentrations of atorvastatin, after which cell
proliferation was measured by [3H]thymidine incorporation. Ator-
vastatin inhibited proliferation in a dose-dependent fashion from
484±4×103 dpm in untreated cells up to 262±9×103 dpm at
the highest concentration of 25M of atorvastatin (equals 0.003%,
P<0.001, Fig. 5A), suggesting that atorvastatin indeed inhibits
endothelial growth as seen in vivo. Interestingly, atorvastatin treat-
ment did not affect the formation of endothelial sprouts in a
Matrigel assay, as measured by the number of cellular extensions
per mm2 cellular surface area (P =NS, Fig. 5B).
4. Discussion
In this study, we demonstrate that atorvastatin inhibits perivas-
cular neovascularization and lesion development in apoE−/− mice
independently of plasma cholesterol levels. HMG-CoA reductase
inhibitors or statins are widely used in lipid-lowering therapy, but
evidence is accumulating that statins may not only act atheropro-
tective by lowering cholesterol levels but also by modulation of
NKB, PPAR and PPAR dependent responses [4–7]. These tran-
scription factors have been demonstrated to affect inﬂammation
but have recently also been implicated in the process of angiogen-
esis [8–12]. As this is an independent risk factor for atherosclerosis
it is conceivable that the beneﬁcial effects of statin treatment may
at least partly proceed by inhibition of neovascularization. Litera-
ture on statin treatment and angiogenesis is rather conﬂicting, as
a number of studies demonstrate pro-angiogenic effects of statins.
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Here, we hypothesized that statins may have a beneﬁcial
effect on perivascular angiogenesis in a model of collar-induced
atherosclerosis in mice because of its PPAR and NFB modulatory
activity. Western-type diet fed apoE−/− mice, treated with atorvas-
tatin (0.003% inwestern-typediet) showed reduced atherosclerotic
lesion progression independently of plasma cholesterol levels.
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n general or possibly by reduced apoptosis of plaque leukocytes
26]. Strikingly, we observed a signiﬁcant reduction of the CD31+
icrovessel content in adventitial tissue of atorvastatin treated
laques. These ﬁndings concur with our in vitro data that show
hat atorvastatin inhibits endothelial cell proliferation at all tested
oncentrations, while not affecting endothelial sprouting. Our data
onﬁrm previous studies by Wilson et al. [17] reporting reduced
asa vasorum formation in pigs after simvastatin treatment. Also,
erivastatin studies showed similar effects on endothelial cell pro-
iferation and in vivo angiogenesis in a matrigel setup [18,19]. Our
tudy demonstrates that atorvastatin inhibits perivascular neo-
ascularization in an in vivo model of atherosclerosis. These data
urthermore suggest thatperivascular angiogenesismaycontribute
o plaque progression and indeed can be regarded a risk factor in
therosclerosis as described earlier [8]. Finally, they demonstrate
n additional atheroprotective feature of statin treatment.
In conclusion, atorvastatin treatment was seen to inhibit plaque
evelopment in ApoE deﬁcient mice independent of plasma total
holesterol levels. The concomitant inhibitory effect of atorvas-
atin on adventitial neovascularization fuels the intriguing notion
hat part of its beneﬁcial effects occurs via this pathway. Thus,
he present data suggest that inhibition of neovascularization is
n additional mechanism by which atorvastatin treatment may
revent the development and progression of atherosclerosis.
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